碧桂園(02007.HK)三亞畔山翠堤項目如期交付 涉1,072伙
碧桂園(02007.HK)公布,位於海南三亞的安居房項目「三亞碧桂園畔山翠堤」於10月30日完成第二批,涉及469伙,連同今年7月底首批交付,項目全數合共1,072個單位已如期交付。
碧桂園畔山翠堤安居房項目採用裝配式建造工藝,總體裝配率達到53%,可有效縮短工期,同時避免出現外牆滲漏、牆體開裂等問題。
集團表示,自2021年海南啟動「交房即交證」試點以後,旗下當地三個安居房項目海口碧桂園劍橋郡、碧桂園三亞郡及三亞碧桂園畔山翠堤均已如期交付,合共涉及2,022個住宅單位,預期有助推動海南自貿港住房保障體系建設。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.